| 8.15 -0.17 (-2.04%) | 05-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.01 | 1-year : | 14.03 |
| Resists | First : | 10.28 | Second : | 12.01 |
| Pivot price | 7.38  |
|||
| Supports | First : | 6.86 | Second : | 4.75 |
| MAs | MA(5) : | 8.43 |
MA(20) : | 6.91 |
| MA(100) : | 4.48 |
MA(250) : | 3.82 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 67 |
D(3) : | 74.4 |
| RSI | RSI(14): 63.2 |
|||
| 52-week | High : | 10.28 | Low : | 1.86 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BNTC ] has closed below upper band by 31.7%. Bollinger Bands are 203.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 18 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.27 - 8.33 | 8.33 - 8.38 |
| Low: | 7.93 - 7.99 | 7.99 - 8.03 |
| Close: | 8.07 - 8.16 | 8.16 - 8.23 |
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Wed, 01 May 2024
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference - Yahoo Finance
Thu, 18 Apr 2024
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b ... - GlobeNewswire
Thu, 18 Apr 2024
Why Is Benitec Biopharma Stock Trading Higher On Thursday? - Benitec Biopharma (NASDAQ:BNTC) - Benzinga
Thu, 18 Apr 2024
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million - GlobeNewswire
Tue, 09 Apr 2024
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular ... - GlobeNewswire
Thu, 30 Nov 2023
Here's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders Concerns - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 1.57e+006 (%) |
| Held by Institutions | 10.4 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.16e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -35 % |
| Return on Assets (ttm) | 560.6 % |
| Return on Equity (ttm) | -81.6 % |
| Qtrly Rev. Growth | 61000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -174.81 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -236.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 1.39 |
| Dividend | 0 |
| Forward Dividend | 12220 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|